A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation

(2013) David Kremer et al.   ANNALS OF NEUROLOGY

Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study

(2013) Giannina Arru et al.   Multiple Sclerosis Journal

Effects of Interferon �-1a and Interferon �-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study

(2013) Adam Stepien et al.   NEUROIMMUNOMODULATION

Novel therapeutic options for multiple sclerosis

(2013) François Curtin et al.   Expert Review of Clinical Pharmacology

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

(2012) François Curtin et al.   CLINICAL THERAPEUTICS

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease

(2012) Hervé Perron et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism

(2011) Jaime Ramos-Cejudo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis

(2010) S. Sotgiu et al.   Multiple Sclerosis Journal

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inhibition of multiple sclerosis–associated retrovirus as biomarker of interferon therapy

(2008) Giuseppe Mameli et al.   JOURNAL OF NEUROVIROLOGY